The provided source material details specific programmes offered by the manufacturer of Eliquis (apixaban), a prescription anticoagulant medication. The information is derived exclusively from official terms and conditions pages associated with these programmes. It is important to note that the documentation specifies eligibility and validity primarily for residents of the United States, Puerto Rico, and other select U.S. territories. The material does not contain information regarding equivalent programmes, free samples, or promotional offers available to residents of the United Kingdom or other regions outside the specified U.S. territories. Consequently, this article is based solely on the details provided for the U.S.-based programmes.
Programme Overview and Core Offer
The source material outlines two distinct financial assistance programmes for eligible patients prescribed Eliquis: a Free 30-Day Trial offer and a Co-pay Card programme. Both are managed through the Eliquis® 360 Support initiative.
The Free 30-Day Trial offer provides a complimentary 30-day supply of Eliquis, which consists of up to 74 tablets. To redeem this offer, a patient must present a Free 30-Day Trial card along with a valid 30-day prescription for Eliquis at a participating pharmacy. The patient is responsible for any applicable taxes associated with the transaction. The terms explicitly state that this offer cannot be redeemed for prescriptions written for a duration longer than 30 days.
The Co-pay Card programme is designed to reduce the out-of-pocket cost for commercially insured patients. Eligible individuals may pay as little as $10 for a 30-day supply or $10 for their first 90-day supply of Eliquis. For subsequent 90-day refills, patients may pay as little as $30, for up to 24 months. There is a maximum annual benefit of $2,000 associated with this card.
Eligibility Requirements
Eligibility criteria for both programmes are stringent and are based on a patient's insurance status, medical history, and residency.
Free 30-Day Trial Eligibility
To be eligible for the Free 30-Day Trial, an individual must meet all of the following conditions: * They must not have previously filled a prescription for Eliquis. * They must possess a valid 30-day prescription for Eliquis. * The prescription must be for an FDA-approved indication, and the healthcare professional must have planned for more than 35 days of treatment. * They must be 18 years of age or older. * They must be a resident of the United States, Puerto Rico, or other select U.S. territories.
Co-pay Card Eligibility
The Co-pay Card has a different set of eligibility requirements, focusing on insurance coverage: * The patient must be insured by commercial insurance, and their prescription insurance coverage must not cover the full cost of the Eliquis prescription (i.e., they have a co-pay obligation). * The patient must not have prescription insurance coverage through any state or federal healthcare programme. This includes, but is not limited to, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), or Department of Defense (DOD) programmes. Patients who transition from commercial plans to state or federal programmes will become ineligible. * The patient must be 18 years of age or older. * The patient must be a resident of the United States, Puerto Rico, or other select U.S. territories.
Terms and Conditions of Use
Both programmes come with specific terms that govern their use and limitations.
General Restrictions
- The Free 30-Day Trial is limited to one use per patient per lifetime and is non-transferable. By redeeming the offer, the patient certifies they have not previously filled a Eliquis prescription.
- The Free 30-Day Trial cannot be combined with any other rebate, coupon, free trial, or similar offer. No substitutions are permitted.
- Patients, pharmacists, and prescribers cannot seek reimbursement for the Free 30-Day Trial from health insurance or any third party, including state or federally funded programmes.
- Patients may not count the Free 30-Day Trial as an expense for determining out-of-pocket costs, including true out-of-pocket (TrOOP) costs, for calculating thresholds for Medicare Part D plans.
Programme Validity and Expiry
- For the Free 30-Day Trial, activation and use of the card must take place by December 31, 2026. The card expires on this date. (Note: An older version of the terms cited in the source material lists an expiry date of December 31, 2024, but the most recent applicable date is 2026).
- The programmes are only valid in the United States, Puerto Rico, and other select U.S. territories.
How to Access and Activate the Programmes
The source material provides specific instructions for patients and pharmacists.
For the Free 30-Day Trial, patients must obtain a Free 30-Day Trial card from their healthcare professional. Once obtained, the card must be activated before it can be used at a participating pharmacy. Activation can be completed online via the manufacturer's website or by calling 1-855-ELIQUIS (354-7847). The manufacturer also offers a virtual assistant named "Elise" for help.
For processing assistance with either programme, pharmacists are directed to call McKesson Pharmacy Support at 1-866-279-4730.
Patients with questions can also submit inquiries via mail to: P.O. Box 2914, Phoenix, AZ, 85062-2914.
Important Considerations for UK Consumers
The provided documentation is exclusively for U.S.-based programmes. There is no mention of free samples, trial programmes, or financial assistance offers available to residents of the United Kingdom, European Union, or other regions. The eligibility criteria are strictly limited to residents of the United States and its territories, and the programmes are tied to the U.S. healthcare system, FDA regulations, and U.S. insurance structures (including Medicare and Medicaid).
UK residents seeking information about Eliquis or similar prescription medications should consult with their General Practitioner (GP) or pharmacist. Any patient assistance programmes or free trial offers for prescription medications in the UK would be governed by the National Health Service (NHS) and Medicines and Healthcare products Regulatory Agency (MHRA) regulations, which are distinct from the U.S. system detailed in the source material.
Conclusion
The source material provides detailed terms for two U.S.-specific financial assistance programmes for Eliquis: a Free 30-Day Trial and a Co-pay Card. Both programmes have strict eligibility criteria centred on insurance status, prior prescription history, and residency within the United States, Puerto Rico, or other select U.S. territories. The Free 30-Day Trial is limited to new patients and expires on December 31, 2026, while the Co-pay Card is for commercially insured patients with a co-pay obligation. For UK consumers, these programmes are not applicable, and any interest in prescription medication assistance should be directed towards the NHS or relevant UK healthcare providers.